Cyclo Therapeutics, Inc. Common Stock
CYTH
CYTH was delisted on the 25th of March, 2025.
16 hedge funds and large institutions have $820K invested in Cyclo Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
7% more funds holding
Funds holding: 15 → 16 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
55% less capital invested
Capital invested by funds: $1.83M → $820K (-$1.01M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$26.3K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.2K |
| 3 |
SSG
Summit Securities Group
New York
|
+$2.45K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$427 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$14 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$465K |
| 2 |
LPL Financial
San Diego,
California
|
-$14.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.66K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$26 |
CYTH Hedge Fund Activity: Q1 2023 in Review
16 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q1 2023, worth a combined $820K — down 55% from $1.83M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CYTH positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $26.3K. The largest seller was Armistice Capital, cutting an estimated $465K.
- 16 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q1 2023, up from 15 in Q4 2022.
- Funds reported $820K of Cyclo Therapeutics, Inc. Common Stock stock for Q1 2023, down 55% quarter-over-quarter.
- 3 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q1 2023 and 2 closed out, a net change of +1 holder.
- The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q1 2023 was Citadel Advisors, an estimated $26.3K added.
- The largest Cyclo Therapeutics, Inc. Common Stock seller in Q1 2023 was Armistice Capital, an estimated $465K sold.
Based on aggregated 13F filings for Q1 2023.